20Sense | Research & Consulting

These ongoing developments could help move the needle on drug access https://lnkd.in/eWSWqe77 ➡️ Timely access to novel medications depends not only on access pathways, but on wider social and political forces. Here, we call out three new developments that will likely cause ripples in Canada’s access landscape. We’re in for some interesting times. #Canada #patientsfirst #access #drugs #pharmaceuticals #drugaccess #managedaccess #HTA #healthequity #patientequity #equity #equality #RWE #RWD #realworlddata #realworldevidence #healthoutcomes #data #patientsupport #specialtypharmaceuticals

NEW REPORT // Full Speed Ahead on Drug Access in Canada https://lnkd.in/emPUukfF #Canada #patientsfirst #access #drugs #pharmaceuticals #drugaccess #managedaccess #HTA #healthequity #patientequity #equity #equality #RWE #RWD #realworlddata #realworldevidence #healthoutcomes #data #patientsupport #specialtypharmaceuticals

For more than two decades, Sophie Rochon has been a leader in Canadian health policy and patient access for novel pharmaceutical products. https://lnkd.in/gc9qmgj2 We caught up with her to get her perspectives on how the market access environment has changed over the past decade, and how companies can be prepared to meet new challenges today and in the future. #Canada #healthequity #patientequity #equity #equality #RWE #RWD #realworlddata #realworldevidence #healthoutcomes #data #patientsfirst #access #drugs #pharmaceuticals #drugaccess

Editorial // New Pathways, Old Problems: Is Patient Access to New Medications Improving in Canada? https://lnkd.in/g-3iZTjf The latest article from 20Sense | Research & Consulting and Dr. Cathy Lau, published in the Journal of Pharmacy and Pharmaceutical Sciences discusses the early impact of recent Canadian reforms designed to accelerate drug access, including Canada's Drug Agency’s Time-limited Recommendation (#TLR) category, the pan-Canadian Pharmaceutical Alliance’s (pCPA) Early Negotiation Process (#ENP), and Ontario’s Funding Accelerated for Specific Treatments (#FAST) 3-year pilot program. Further to the early successes of these pathways, access gaps remain. Strategies for tangible, timely access solutions are suggested, including: 🚦 Continuing to prioritize operational efficiencies at the pCPA; 💳 Establishing protected funding for innovation; 📈 Focus on continuous policy and process evolution. 🤲 Establishing a pathway for joint pricing models for high-cost therapies and drugs for rare diseases.

As a sponsor of the 10th anniversary edition of The 20Sense Report, we reflect on a decade of resilience, innovation, and partnership that has shaped Canada’s healthcare journey. At Innomar Strategies, we’re honored to continue driving progress in specialty drug access and patient care. “Resilience isn’t just about infrastructure, but about people, partnerships, and the ability to respond to extraordinary pressures without losing sight of the individual patient.” – Guy Payette, Senior Vice President and President, Global Pharmaceutical Services and Innomar Strategies From distributing over 50 million doses of Covid-19 vaccines to leveraging technology and data-driven insights to serve patients, we remain committed to creating healthier futures through innovation, collaboration, and sustainable care solutions. Read the full report here: https://lnkd.in/gudE2ZD2 20Sense | Research & Consulting

NEW REPORT // A decade of pharmaceutical data, discovery, and determination in Canada https://lnkd.in/gudE2ZD2 #Canada #healthequity #patientequity #equity #equality #RWE #RWD #realworlddata #realworldevidence #healthoutcomes #data #patientsupport #patientsfirst #access #drugs #pharmaceuticals #drugaccess #managedaccess #HTA #specialtypharmaceuticals #access

In the news, Jan. 16, 2026: An opinion piece about Canada's Drug Agency and the timeliness of access to medicines in Canada https://lnkd.in/gUKk_TqN #Canada #pharmaceuticals #access #drugs

In the news, Jan. 9, 2026: "Today, a clinical team in the Hurvitz Brain Sciences Program has taken the next step in advancing dementia care by performing Canada’s first patient infusion of #lecanemab, a disease-modifying therapy used to treat mild cognitive impairment or mild dementia caused by #Alzheimer’s #disease" ➡️ Of note: "Currently, lecanemab is not funded or reimbursed by provincial health insurance plans or the public health care system in Canada, and as such is only available through self-payment." https://lnkd.in/gSCJ9kMY #Canada #pharmaceuticals #access #drugs

NEW REPORT // Canadian Health Equity Changemakers https://lnkd.in/gRkdraNf CC: Arif Mitha Allison Wills Novartis Canada Amber Dyce Sossy Meguerdij AQCAMO - Association québécoise des coordonnateurs d'accès aux médicaments d'oncologie Gail Ouellette Regroupement québécois des maladies orphelines GI (Gastrointestinal) Society | badgut.org Breast Cancer Canada

NEW REPORT // Understanding Health Canada’s accelerated drug approval pathways https://lnkd.in/g_dNAnbu #Canada #regulatory #drugapproval #ProjectOrbis #healthequity #patientequity #equity #equality #RWE #RWD #realworlddata #realworldevidence #healthoutcomes #data #patientsupport #patientsfirst #access #drugs #pharmaceuticals #drugaccess #managedaccess #HTA #specialtypharmaceuticals #access CC: Arif Mitha Allison Wills Health Canada | Santé Canada